DRD4
D(4) dopamine receptor
Also known as: DRD4_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P21917
- Gene
- DRD4
- Ensembl
- ENSG00000069696
- Chromosome
- 11
- Canonical length
- 419 aa
- Protein class
- FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins
- Subcellular location
- Plasma membrane,Centrosome
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes the D4 subtype of the dopamine receptor. The D4 subtype is a G-protein coupled receptor which inhibits adenylyl cyclase. It is a target for drugs which treat schizophrenia and Parkinson disease. Mutations in this gene have been associated with various behavioral phenotypes, including autonomic nervous system dysfunction, attention deficit/hyperactivity disorder, and the personality trait of novelty seeking. This gene contains a polymorphic number (2-10 copies) of tandem 48 nt repeats; the sequence shown contains four repeats. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
419 residues, UniProt reviewed canonical sequence.
>P21917|DRD4
1 MGNRSTADAD GLLAGRGPAA GASAGASAGL AGQGAAALVG GVLLIGAVLA GNSLVCVSVA
61 TERALQTPTN SFIVSLAAAD LLLALLVLPL FVYSEVQGGA WLLSPRLCDA LMAMDVMLCT
121 ASIFNLCAIS VDRFVAVAVP LRYNRQGGSR RQLLLIGATW LLSAAVAAPV LCGLNDVRGR
181 DPAVCRLEDR DYVVYSSVCS FFLPCPLMLL LYWATFRGLQ RWEVARRAKL HGRAPRRPSG
241 PGPPSPTPPA PRLPQDPCGP DCAPPAPGLP RGPCGPDCAP AAPSLPQDPC GPDCAPPAPG
301 LPPDPCGSNC APPDAVRAAA LPPQTPPQTR RRRRAKITGR ERKAMRVLPV VVGAFLLCWT
361 PFFVVHITQA LCPACSVPPR LVSAVTWLGY VNSALNPVIY TVFNAEFRNV FRKALRACCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DRD4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 3.9 nTPM
Expression across tissuesHPA
Tissue
- pituitary gland: 3.9 nTPM
- cerebellum: 3.6 nTPM
- ovary: 3.4 nTPM
- hippocampal formation: 2.7 nTPM
- hypothalamus: 2.4 nTPM
- testis: 2.4 nTPM
Single-cell type
- rod photoreceptor cells: 50 nCPM
- retinal pigment epithelial cells: 43 nCPM
- pdcs: 17 nCPM
- ependymal cells: 15 nCPM
- retinal bipolar cells: 12 nCPM
- choroid plexus epithelial cells: 9.8 nCPM
Immune cell
- plasmacytoid DC: 0.9 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebellum: 5.3 nTPM
- white matter: 3.9 nTPM
- pons: 3.7 nTPM
- basal ganglia: 3.6 nTPM
- cerebral cortex: 3.6 nTPM
- thalamus: 3.6 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DRD4.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 208 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hereditary attention deficit-hyperactivity disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.86
- gnomAD pLI
- 0
- gnomAD missense Z
- -2
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-inhibiting dopamine receptor signaling pathway
- adenylate cyclase-modulating G protein-coupled receptor signaling pathway
- adult locomotory behavior
- arachidonate secretion
- behavioral fear response
- behavioral response to cocaine
- behavioral response to ethanol
- chemical synaptic transmission
- fear response
- G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
- inhibitory postsynaptic potential
- intracellular calcium ion homeostasis
- negative regulation of protein secretion
- phospholipase C-activating dopamine receptor signaling pathway
- positive regulation of dopamine uptake involved in synaptic transmission
- positive regulation of MAPK cascade
- regulation of circadian rhythm
- regulation of dopamine metabolic process
- regulation of postsynaptic neurotransmitter receptor internalization
- response to amphetamine
- response to histamine
- rhythmic process
- social behavior
Molecular functions
- dopamine binding
- dopamine neurotransmitter receptor activity
- dopamine neurotransmitter receptor activity, coupled via Gi/Go
- epinephrine binding
- G protein-coupled serotonin receptor activity
- identical protein binding
- metal ion binding
- neurotransmitter receptor activity
- norepinephrine binding
- potassium channel regulator activity
- SH3 domain binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DRD4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DRD4 as an antibody target. Whether an autoantibody or antibody against DRD4 could matter depends on whether native DRD4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DRD4 is annotated at the cell surface, where native DRD4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label DRD4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...